Comparative Pharmacology
Head-to-head clinical analysis: ESIDRIX versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 100 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESIDRIX versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 100 50.
ESIDRIX vs HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption, leading to increased diuresis and decreased extracellular volume.
Hydralazine: Direct vasodilation of arterioles via unknown mechanism, possibly involving nitric oxide. Hydrochlorothiazide: Thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.
25-50 mg orally once daily; may increase to 100 mg once daily or 50 mg twice daily for resistant edema.
1 tablet (hydralazine 100 mg / hydrochlorothiazide 50 mg) orally once daily. Maximum: 1 tablet daily. Titrate from lower doses of individual components.
None Documented
None Documented
Terminal elimination half-life is approximately 10-15 hours (mean 12 hours); clinical context: half-life prolonged in renal impairment, requiring dose adjustment.
Hydralazine: 2-8 hours (prolonged in renal impairment); Hydrochlorothiazide: 6-15 hours (increased in renal impairment)
Renal: approximately 70% excreted unchanged in urine; biliary/fecal: less than 10%.
Hydralazine: 90% renal metabolites, 10% feces; Hydrochlorothiazide: >95% renal (tubular secretion) as unchanged drug
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic